Optimal management strategies for chronic iron overload
- PMID: 17385941
- DOI: 10.2165/00003495-200767050-00004
Optimal management strategies for chronic iron overload
Abstract
Iron overload is characterised by excessive iron deposition and consequent injury and dysfunction of target organs, especially the heart, liver, anterior pituitary, pancreas and joints. Iron overload disorders are common worldwide and occur in most major race/ethnicity groups. Physiological mechanisms to excrete iron are very limited. Thus, all patients with iron overload need safe and effective treatment that is compatible with their co-existing medical conditions. Treatments for iron overload include phlebotomy and erythrocytapheresis that remove iron predominantly as haemoglobin, and chelation therapy with drugs that bind excess iron selectively and increase its excretion. The most important potential benefits of therapy are preventing deaths due to cardiac siderosis and hepatic cirrhosis. Preventing iron-related injury to endocrine organs is critical in children. Successful treatment or prevention of iron overload increases quality of life and survival in many patients. This article characterises the major categories of iron overload disorders, tabulates methods to evaluate and treat iron overload, and describes treatment options for iron overload disorders. Research needed to advance knowledge about treatment of iron overload is proposed.
Similar articles
-
[Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)].Bull Cancer. 2016 Nov;103(11S):S255-S266. doi: 10.1016/j.bulcan.2016.09.003. Epub 2016 Nov 11. Bull Cancer. 2016. PMID: 27842863 French.
-
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.Pharmacotherapy. 2008 Mar;28(3):331-42. doi: 10.1592/phco.28.3.331. Pharmacotherapy. 2008. PMID: 18294113 Review.
-
Iron mobilization using chelation and phlebotomy.J Trace Elem Med Biol. 2012 Jun;26(2-3):127-30. doi: 10.1016/j.jtemb.2012.03.009. Epub 2012 May 5. J Trace Elem Med Biol. 2012. PMID: 22565013 Review.
-
Iron overload and toxicity: the hidden risk of multiple blood transfusions.Vox Sang. 2009 Oct;97(3):185-97. doi: 10.1111/j.1423-0410.2009.01207.x. Epub 2009 Aug 3. Vox Sang. 2009. PMID: 19663936 Review.
-
Evaluation and treatment of transfusional iron overload in children.Pediatr Clin North Am. 2013 Dec;60(6):1393-406. doi: 10.1016/j.pcl.2013.09.003. Pediatr Clin North Am. 2013. PMID: 24237978 Review.
Cited by
-
Effect of tannic acid-templated mesoporous silica nanoparticles on iron-induced oxidative stress and liver toxicity in rats.Toxicol Rep. 2021 Oct 1;8:1721-1728. doi: 10.1016/j.toxrep.2021.09.005. eCollection 2021. Toxicol Rep. 2021. PMID: 34692422 Free PMC article.
-
Iron chelation therapy in thalassemia syndromes.Mediterr J Hematol Infect Dis. 2009 Dec 29;1(1):e2009034. doi: 10.4084/MJHID.2009.034. Mediterr J Hematol Infect Dis. 2009. PMID: 21415999 Free PMC article.
-
Early Cardiac Iron Overload in a Child on Treatment of Acute Lymphoblastic Leukemia.Pediatrics. 2015 Sep;136(3):e697-700. doi: 10.1542/peds.2014-3770. Epub 2015 Aug 17. Pediatrics. 2015. PMID: 26283784 Free PMC article.
-
Synthetic and natural iron chelators: therapeutic potential and clinical use.Future Med Chem. 2009 Dec;1(9):1643-70. doi: 10.4155/fmc.09.121. Future Med Chem. 2009. PMID: 21425984 Free PMC article. Review.
-
Deferasirox : a review of its use in the management of transfusional chronic iron overload.Drugs. 2007;67(15):2211-30. doi: 10.2165/00003495-200767150-00007. Drugs. 2007. PMID: 17927285 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources